as of —
₹—
Change
—
Day Open
₹—
Day High
₹—
Day Low
₹—
NSE Close — 19 Nov 2026
₹191.78
Change
+2.04 (1.08%)
Open
₹189.74
Prev. Close
₹189.74
Day High
₹194.2
Day Low
₹186.05
Volume Analysis
Traded
1,388,012
Delivered
401,195
Delivery %
28.9%
End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.
Strengths, Weaknesses, Opportunities & Threats
Strengths (1)
- •Promoter holding is rising
Weaknesses (1)
- •Low return on equity (8.41%)
Opportunities (1)
- •FII holding has been rising
Threats (0)
No signal for this stock
Rule-based signals from the fundamentals below — not investment advice.
Pivot Levels
| Type | R3 | R2 | R1 | Pivot | S1 | S2 | S3 |
|---|---|---|---|---|---|---|---|
| Classic | ₹203.46 | ₹198.83 | ₹195.31 | ₹190.68 | ₹187.16 | ₹182.53 | ₹179.01 |
| Fibonacci | ₹198.83 | ₹195.72 | ₹193.79 | ₹190.68 | ₹187.57 | ₹185.64 | ₹182.53 |
| Camarilla | ₹194.02 | ₹193.27 | ₹192.53 | ₹190.68 | ₹191.03 | ₹190.29 | ₹189.54 |
Support/resistance levels for today, calculated from the previous trading day's high/low/close.
Absolute Returns
YTD
+133.37%
1 Week
-6.49%
1 Month
+10.07%
3 Months
+13.13%
6 Months
+61.53%
1 Year
+109.32%
2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.
Stock Vitals
Computed from the latest available annual financials.
Graham Number
₹149.54
Current price is above the Graham Number — Benjamin Graham's estimate of fair value based on earnings and book value.
DuPont ROE Breakdown
11.52%
Net margin 7.38% × asset turnover 1.22x × equity multiplier 1.28x
Company Overview
Sector
Healthcare
Market Cap
₹5,587 Cr
P/E (TTM)
26.4
ROE
8.41%
Book Value
₹65.6
Face Value
₹2.0
Source: Screener.in (Consolidated figures) — data as of 17 Nov 2026. Not investment advice.
TopFund Analysis
Iol Chem And Pharma Ltd lands in the middle of the pack on TopFund's composite fundamentals check within the Healthcare sector, at 59/100. The strongest factor is Financial Strength (100/100), while Growth (6/100) is the weakest area to weigh before deciding. Notably: Promoter holding is rising; low return on equity (8.41%). FII holding has been rising.
TopFund Score — Fundamentals Quality
59/100 — AverageData confidence: 80/100 (High Confidence) — based on how complete and how fresh the underlying data is.
As of 19 Nov 2026 · How we calculate this →
Financial Strength
Growth
Valuation
Cash Flow
Corporate Governance
Momentum
Institutional Ownership
Business Quality
Risk & Volatility
Liquidity
From Screener.in
- +Company is expected to give good quarter
- +Company has been maintaining a healthy dividend payout of 22.1%
- −Stock is trading at 2.91 times its book value
- −Company has a low return on equity of 7.72% over last 3 years.
Not investment advice — an automated read of public fundamentals data, for research context only.
Corporate Actions
Company clarified no undisclosed event behind recent trading volume increase.
Exchange has sought clarification from IOL Chemicals & Pharmaceuticals Ltd on November 11, 2026, with reference to Movement in Volume.
Transcript of Earning Call on the Q2 & H1 FY27 Financial Results
Audio recording released for Q2 and H1 FY27 earnings call held on 2 November 2026.
Investor Presentation- Q2 & H1 FY27
Source: BSE regulatory filings, via Screener.in.
Quarterly Results
Last several quarters
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 545 | 520 | 504 | 502 | 526 | 523 | 528 | 552 | 568 | 580 | 619 | 756 | 795 |
| Expenses + | 481 | 476 | 454 | 451 | 484 | 476 | 465 | 490 | 510 | 523 | 527 | 653 | 686 |
| Operating Profit | 64 | 44 | 50 | 51 | 42 | 47 | 63 | 62 | 57 | 57 | 92 | 103 | 109 |
| OPM % | 12.0% | 9.0% | 10.0% | 10.0% | 8.0% | 9.0% | 12.0% | 11.0% | 10.0% | 10.0% | 15.0% | 14.0% | 14.0% |
| Other Income + | 7 | 8 | 8 | 7 | 6 | 4 | 5 | 7 | 7 | -6 | 2 | 8 | 6 |
| Interest | 4 | 4 | 3 | 2 | 4 | 4 | 4 | 4 | 3 | 4 | 3 | 4 | 5 |
| Depreciation | 16 | 16 | 16 | 17 | 18 | 19 | 19 | 20 | 20 | 20 | 20 | 21 | 22 |
| Profit before tax | 51 | 32 | 37 | 40 | 26 | 28 | 45 | 46 | 40 | 28 | 71 | 87 | 87 |
| Tax % | 26.0% | 28.0% | 26.0% | 24.0% | 26.0% | 26.0% | 30.0% | 25.0% | 26.0% | 25.0% | 25.0% | 26.0% | 25.0% |
| Net Profit + | 38 | 23 | 28 | 30 | 19 | 21 | 31 | 34 | 30 | 21 | 53 | 64 | 65 |
| EPS in Rs | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 2 |
| Raw PDF | — | — | — | — | — | — | — | — | — | — | — | — | — |
| YoY Sales growth | 1 | -1 | -14 | -11 | -4 | 1 | 5 | 10 | 8 | 11 | 17 | 37 | 40 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Profit & Loss (Yearly)
| Mar 2015 (S) | Mar 2016 (S) | Mar 2017 (S) | Mar 2018 (S) | Mar 2019 (S) | Mar 2020 (S) | Mar 2021 (S) | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 385 | 580 | 711 | 983 | 1,685 | 1,894 | 1,967 | 2,184 | 2,217 | 2,133 | 2,079 | 2,319 | 2,751 |
| Expenses + | 373 | 529 | 608 | 863 | 1,276 | 1,321 | 1,375 | 1,925 | 1,991 | 1,902 | 1,877 | 2,049 | 2,388 |
| Operating Profit | 11 | 51 | 102 | 120 | 410 | 574 | 592 | 259 | 226 | 231 | 202 | 270 | 363 |
| OPM % | 2.9% | 9.0% | 14.0% | 12.0% | 24.0% | 30.0% | 30.0% | 12.0% | 10.0% | 11.0% | 10.0% | 12.0% | 13.0% |
| Other Income + | 1 | 1 | 1 | 6 | 10 | 16 | 24 | 17 | 25 | 30 | 22 | 9 | 10 |
| Interest | 59 | 61 | 68 | 64 | 51 | 21 | 6 | 8 | 16 | 16 | 15 | 15 | 16 |
| Depreciation | 29 | 30 | 30 | 30 | 32 | 36 | 39 | 43 | 46 | 63 | 72 | 80 | 84 |
| Profit before tax | -75 | -39 | 6 | 31 | 336 | 533 | 571 | 225 | 189 | 182 | 138 | 184 | 272 |
| Tax % | -12.0% | 4.0% | 21.0% | 12.0% | 30.0% | 32.0% | 22.0% | 25.0% | 26.0% | 26.0% | 27.0% | 25.0% | — |
| Net Profit + | -67 | -40 | 5 | 28 | 237 | 361 | 445 | 168 | 139 | 134 | 101 | 138 | 203 |
| EPS in Rs | -3 | -1 | 0 | 1 | 8 | 13 | 15 | 6 | 5 | 5 | 3 | 5 | 7 |
| Dividend Payout % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 5.0% | 8.0% | 14.0% | 17.0% | 22.0% | 23.0% | 21.0% | — |
| Sales growth | -32 | 51 | 22 | 38 | 71 | 12 | 4 | — | 2 | -4 | -3 | 12 | 27 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Balance Sheet
| Mar 2015 (S) | Mar 2016 (S) | Mar 2017 (S) | Mar 2018 (S) | Mar 2019 (S) | Mar 2020 (S) | Mar 2021 (S) | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reserves | 160 | 129 | 132 | 160 | 417 | 757 | 1,202 | 1,334 | 1,449 | 1,553 | 1,629 | 1,740 | 1,867 |
| Borrowings + | 400 | 453 | 447 | 422 | 284 | 59 | 3 | 44 | 80 | 33 | 117 | 135 | 201 |
| Other Liabilities + | 94 | 135 | 182 | 214 | 184 | 297 | 347 | 526 | 435 | 600 | 577 | 653 | 704 |
| Total Liabilities | 702 | 772 | 817 | 852 | 942 | 1,170 | 1,610 | 1,962 | 2,022 | 2,244 | 2,382 | 2,587 | 2,831 |
| Fixed Assets + | 403 | 400 | 374 | 406 | 412 | 469 | 512 | 561 | 752 | 933 | 1,171 | 1,182 | 1,191 |
| CWIP | 4 | 4 | 21 | 7 | 27 | 19 | 48 | 105 | 90 | 101 | 22 | 96 | 189 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 20 | 20 | 21 | 21 | 21 |
| Other Assets + | 295 | 369 | 422 | 439 | 503 | 682 | 1,048 | 1,294 | 1,161 | 1,190 | 1,169 | 1,289 | 1,429 |
| Total Assets | 702 | 772 | 817 | 852 | 942 | 1,170 | 1,610 | 1,962 | 2,022 | 2,244 | 2,382 | 2,587 | 2,831 |
| Equity Capital | 48 | 56 | 56 | 56 | 57 | 57 | 59 | 59 | 59 | 59 | 59 | 59 | 59 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Cash Flow
| Mar 2015 (S) | Mar 2016 (S) | Mar 2017 (S) | Mar 2018 (S) | Mar 2019 (S) | Mar 2020 (S) | Mar 2021 (S) | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity + | -47 | 18 | 83 | 120 | 273 | 471 | 380 | 93 | 122 | 290 | 179 | 214 |
| Cash from Investing Activity + | -5 | -27 | -23 | -50 | -63 | -184 | -317 | -121 | -120 | -191 | -154 | -198 |
| Cash from Financing Activity + | 50 | 9 | -60 | -70 | -197 | -272 | -58 | -2 | -4 | -92 | 46 | -29 |
| Net Cash Flow | -2 | 0 | 1 | -1 | 13 | 15 | 4 | -29 | -2 | 6 | 70 | -13 |
| Free Cash Flow | -53 | -9 | 61 | 71 | 213 | 391 | 272 | -58 | -87 | 17 | -34 | 43 |
| CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit | -413 | 34 | 82 | 105 | 83 | 102 | 88 | 60 | 75 | 144 | 97 | 93 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Shareholding Pattern
Quarter-by-quarter — Promoters, FII, DII & public holding trend
| Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Public | 49.27% | 50.11% | 50.34% | 50.11% | 45.81% | 45.84% | 44.76% | 45.1% | 45.26% | 40.78% | 32.41% | 30.16% |
| Promoters | 48.19% | 48.19% | 48.19% | 48.19% | 52.62% | 52.62% | 52.62% | 52.62% | 52.62% | 57.48% | 62.28% | 62.28% |
| FII | 2.18% | 1.4% | 1.39% | 1.63% | 1.49% | 1.47% | 2.59% | 2.25% | 2.08% | 1.72% | 4.87% | 7.26% |
| DII | 0.36% | 0.29% | 0.09% | 0.07% | 0.08% | 0.07% | 0.02% | 0.05% | 0.03% | 0.02% | 0.43% | 0.3% |
Source: Screener.in — quarterly shareholding disclosures.
Peers Comparison
Healthcare — ranked by market cap
| Company | Market Cap (Cr) | P/E | P/B | ROE |
|---|---|---|---|---|
| Iol Chem And Pharma Ltd (this stock) | 5,587 | 26.4 | 2.91 | 8.41% |
| Sahajanand Medical Tech L | 5,427 | 75.6 | — | 10.4% |
| Artemis Med Service Ltd | 5,415 | 46.2 | 5.47 | 12.0% |
| Senores Pharmaceuticals L | 5,409 | 40.5 | 5.39 | 13.4% |
| Orchid Pharma Limited | 5,296 | 293.0 | 2.95 | 1.49% |
| Innova Captab Limited | 5,938 | 35.6 | 5.09 | 13.7% |
| Morepen Lab. Ltd | 5,061 | 26.8 | 3.67 | 5.33% |
Which Mutual Funds Hold Iol Chem And Pharma Ltd?
Frequently Asked Questions about Iol Chem And Pharma Ltd
Iol Chem And Pharma Ltd (IOLCP) closed at ₹191.78 on NSE on 19 November 2026, up 2.04 (1.08%) from the previous close.
Iol Chem And Pharma Ltd trades on the NSE (National Stock Exchange of India) under the symbol IOLCP.
Iol Chem And Pharma Ltd has a trailing twelve-month P/E (price-to-earnings) ratio of 26.4.
Iol Chem And Pharma Ltd has a dividend yield of 0.52%.
Iol Chem And Pharma Ltd's 52-week high is ₹224.0 and its 52-week low is ₹67.1.
Iol Chem And Pharma Ltd has a market capitalisation of ₹5,587 crore.
Iol Chem And Pharma Ltd has a TopFund Quality Score of 59/100 (Average), a composite of profitability, balance-sheet health, growth and valuation. This is an analytical score based on public data, not personalized investment advice — see the full breakdown below before deciding.
Community Sentiment
What are other investors saying about Iol Chem And Pharma Ltd?
No votes yet — be the first to share your view.
Sign in to voteDiscussion
User-generated content — not investment advice, and not verified or endorsed by TopFund.
Sign in to join the discussionNo comments yet — start the discussion.